25 YEARS ONE MISSION empowering muscle empowering lives

Medicines & Research

As a leader in muscle biology, we have a robust pipeline of small molecule muscle activators and inhibitors to address diseases characterized by compromised muscle function, including heart failure, hypertrophic cardiomyopathy (HCM Disease), and neuromuscular diseases.

hcm patient smiling

Commitment to our Mission

Cytokinetics is powered by passion with patients as our North Star. Our mission is to develop new medicines that may improve outcomes for those living with debilitating diseases of cardiovascular and neuromuscular muscle dysfunction.

Corporate Presentation

Learn more about our mission vision, drug development, pipeline and clinical development in our corporate presentation.

History in the making

For more than 25 years, Cytokinetics, a late-stage biopharmaceutical company, has been finding strength in science as a pioneer in the field of muscle biology working to discover, develop, and commercialize potential medicines that may preserve and extend independence in people suffering from debilitating diseases.

See our story

 
1998

Operations began

Company operations begin in South San Francisco.

 
2004

Completed initial public offering

Becomes a publicly traded company, fueling the opportunity to expand and accelerate the development programs.

 
2008

Strategic realignment

Company focuses research activities to muscle biology.

 
2018

Began Phase 1 study of cardiac myosin inhibitor

Clinical trials begin for the first potential cardiac myosin inhibitor.

 
2022

Started SEQUOIA-HCM clinical trial

First Phase 3 clinical trial of potential cardiac myosin inhibitor begins.

Cardiovascular Disease

Cardiovascular disease is the leading cause of death in the U.S., with one person dying from related diseases every 34 seconds.1 We’re committed to building a specialty cardiology business to bring forward treatment options that make a difference for the millions of patients impacted by heart failure and hypertrophic cardiomyopathy.

Cytokinetics is a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases.

Discover Cytokinetics

We are committed to keeping patients at the center of our work, advancing a high integrity, diverse and inclusive culture, and supporting a more sustainable world.

See our responsibility

We provide more than a job. We provide an opportunity to contribute to something bigger than any one of us. We seek exceptional individuals who share our vision of improving the lives of patients with compromised muscle function.

Join us

References

  1. Centers for Disease Control and Prevention, National Center for Health Statistics. About Multiple Cause of Death, 1999-2020. CDC WONDER Online Database website. Atlanta, GA: Centers for Disease Control and Prevention; 2022. Accessed February 21, 2022.